Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPANY REPORTS PRELIMINARY Q2 2026 AUCATZYL NET PRODUCT REVENUE OF APPROXIMATELY $45 MILLION AND GROSS MARGIN OF APPROXIMATELY 35% YEAR-TO-DATE FY 2026 SALES GUIDANCE INCREASED TO $140  $150 MILLION, FROM $120  $135 MILLION CAPITAL BASE STRENGTHENED THROUGH FIVE-YEAR, INTEREST-ONLY CREDIT FACILITY WITH $75 MILLION FUNDED AT CLOSE AUTOLUS TO REPORT Q2 2026 FINANCIAL RESULTS ON AUGUST 11, 2026 LONDON AND GAITHERSBURG, MD., AUG. 03, 2026 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES AND CANDIDATES, TODAY ANNOUNCED PRELIMINARY SECOND QUARTER 2026 AUCATZYL NET PRODUCT REVENUE OF APPROXIMATELY $45 MILLION AND GROSS MARGIN OF APPROXIMATELY 35% YEAR-TO-DATE.

AUTOLUS THERAPEUTICS REPORTS PRELIMINARY SECOND QUARTER 2026 NET PRODUCT REVENUE AND ANNOUNCES CREDIT FACILITY OF UP TO $250 MILLION WITH PERCEPTIVE ADVISORS

LONDON & GAITHERSBURG, MD., JULY 01, 2026 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES AND CANDIDATES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS GRANTED STOCK OPTION AWARDS TO PURCHASE AN AGGREGATE OF 25,420 AMERICAN DEPOSITARY SHARES AND 87,530 RESTRICTED STOCK UNITS (RSUS), EACH REPRESENTING AN EQUAL NUMBER OF ORDINARY SHARES, TO 13 EMPLOYEES PURSUANT TO THE COMPANY'S 2025 INDUCEMENT PLAN.

AUTOLUS THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

LONDON AND GAITHERSBURG, MD., JUNE 25, 2026 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE H.C.

AUTOLUS THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCE

LONDON AND GAITHERSBURG, MD., JUNE 12, 2026 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES AND CANDIDATES, TODAY ANNOUNCED THAT THE GALIEN FOUNDATION HAS PRESENTED THE COMPANY WITH THE 2026 PRIX GALIEN UK AWARD FOR BEST BIOTECHNOLOGY PRODUCT.

AUTOLUS THERAPEUTICS RECEIVES PRIX GALIEN UK AWARD

LONDON AND GAITHERSBURG, MD., MAY 27, 2026 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCES THAT THE COMPANY WILL PRESENT AND HOST MEETINGS AT TWO UPCOMING INVESTOR CONFERENCES.

AUTOLUS THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

LONDON AND GAITHERSBURG, MD., MAY 21, 2026 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES AND CANDIDATES, ANNOUNCES THE ONLINE PUBLICATION OF AN ABSTRACT SUBMITTED TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, TO BE HELD MAY 29  JUNE 2, 2026, IN CHICAGO, ILLINOIS.

AUTOLUS THERAPEUTICS TO PRESENT CLINICAL DATA UPDATE AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING 2026

AUCATZYL (OBECABTAGENE AUTOLEUCEL; OBE-CEL) NET PRODUCT REVENUE OF $26.2 MILLION FOR THE FIRST QUARTER OF 2026, REFLECTING STRONG LAUNCHES IN THE US AND MOST RECENTLY THE UK COMPANY ACHIEVES POSITIVE GROSS MARGIN FOR THE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) BUSINESS COST REDUCTION INITIATIVE TO DRIVE GROSS PROFIT MARGIN IMPROVEMENT AND PATH TO PROFITABILITYFORTHEALL BUSINESSUNDERWAY OBE-CEL CLINICAL DEVELOPMENT PROGRAMS ON TRACK WITH TRIAL ENROLLMENT ONGOING IN LUPUS NEPHRITIS, PEDIATRIC ALL AND PROGRESSIVE MULTIPLE SCLEROSIS (MS) CONFERENCE CALL TO BE HELD TODAY AT 8:30AM EDT/1:30PM BST: CONFERENCE CALL PARTICIPANTS SHOULD PRE-REGISTER USING THE LINK AT THE BOTTOM OF THIS PRESS RELEASE LONDON AND GAITHERSBURG, MD., MAY 14, 2026 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES AND CANDIDATES, TODAY ANNOUNCES ITS OPERATIONAL AND FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026.

AUTOLUS THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATES

LONDON AND GAITHERSBURG, MD., MAY 05, 2026 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), A COMMERCIAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE ITS FIRST QUARTER 2026 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS BEFORE OPEN OF U.S. MARKETS ON THURSDAY, MAY 14, 2026.

AUTOLUS THERAPEUTICS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON MAY 14, 2026

INITIATIVE FOCUSED ON DRIVING GROSS PROFIT MARGIN AND PATH TO PROFITABILITY FOR THE ALL BUSINESS COMPANY WILL REDUCE HEADCOUNT BY APPROXIMATELY 13% WHILE DOUBLING MANUFACTURING OF PRODUCTS FOR COMMERCIAL AND CLINICAL TRIAL PATIENTS IN 2026 AUTOLUS REITERATES FULL YEAR 2026 AUCATZYL NET PRODUCT REVENUE OF $120 MILLION TO $135 MILLION, UP FROM $74 MILLION IN 2025, AS WELL AS AN ANTICIPATED SHIFT TO POSITIVE GROSS MARGIN IN 2026 CLINICAL DEVELOPMENT PROGRAMS ARE ON TRACK AND INCLUDE CATULUS, A PIVOTAL PHASE 2 TRIAL IN PEDIATRIC RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA; LUMINA, A PIVOTAL PHASE 2 TRIAL IN LUPUS NEPHRITIS; AND BOBCAT, AN EXPLORATORY PHASE 1 TRIAL IN PROGRESSIVE MULTIPLE SCLEROSIS LONDON AND GAITHERSBURG, MD., APRIL 29, 2026 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC(NASDAQ: AUTL), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES AND CANDIDATES, TODAY ANNOUNCED A STRATEGIC INITIATIVE AND PLAN TO IMPROVE OPERATIONAL EFFICIENCY AND REDUCE OPERATING EXPENSES.

AUTOLUS THERAPEUTICS ANNOUNCES INITIATIVE TO SUPPORT OPERATIONAL EFFICIENCY AND COST REDUCTION

LONDON AND GAITHERSBURG, MD., APRIL 21, 2026 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES AND CANDIDATES, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS GRANTED STOCK OPTION AWARDS TO PURCHASE AN AGGREGATE OF 68,500 AMERICAN DEPOSITARY SHARES AND 57,765 RESTRICTED STOCK UNITS (RSUS), EACH REPRESENTING AN EQUAL NUMBER OF ORDINARY SHARES, TO 15 EMPLOYEES PURSUANT TO THE COMPANY'S 2025 INDUCEMENT PLAN.

LONDON AND GAITHERSBURG, MD., APRIL 07, 2026 (GLOBE NEWSWIRE) -- AUTOLUS THERAPEUTICS PLC (NASDAQ: AUTL), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING, MANUFACTURING AND DELIVERING NEXT-GENERATION PROGRAMMED T CELL THERAPIES, ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES.

Autolus Therapeutics plc

AUTL

Price

Financial Reports

No items found.

Press Releases

Autolus Therapeutics plc

AUTL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

AUTL